Myosin

Cat.No. Product Name Information Product Use Citations Product Validations
S2623 Omecamtiv mecarbil (CK-1827452) Omecamtiv mecarbil (CK-1827452) is a specific cardiac myosin activator and a clinical drug for left ventricular systolic heart failure, currently in Phase 2.
Nat Biotechnol, 2025, 10.1038/s41587-025-02725-6
Eur Heart J, 2025, ehaf813
Journal of General Physiology, 2025, e202513762
Verified customer review of Omecamtiv mecarbil (CK-1827452)
E6493New MT-125 MT-125 is a first-in-class, brain-penetrant small-molecule inhibitor of NMIIA with a Ki of 2.7 μM and NMIIB with an EC50 of 1.7 μM. It also exhibits significant preclinical activity in glioblastoma (GBM) models.
E6959New BHB-1893 BHB-1893 (HRS-1893) is a selective, reversible cardiac myosin ATPase inhibitor. It reduces actin-myosin crossbridge formation and myocardial hypercontractility, and is being developed for hypertrophic cardiomyopathy (HCM), including obstructive HCM.